174 related articles for article (PubMed ID: 22573933)
1. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.
Golor G; Hu K; Ruffin M; Buchelt A; Bouillaud E; Wang Y; Maldonado M
Drug Des Devel Ther; 2012; 6():71-9. PubMed ID: 22573933
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
Petersenn S; Hu K; Maldonado M; Zhang Y; Lasher J; Bouillaud E; Wang Y; Mann K; Unger N
Clin Ther; 2012 Mar; 34(3):677-88. PubMed ID: 22364824
[TBL] [Abstract][Full Text] [Related]
3. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.
Beglinger C; Hu K; Wang Y; Bouillaud E; Darstein C; Wang Y; Mohideen P
Endocrine; 2012 Oct; 42(2):366-74. PubMed ID: 22527887
[TBL] [Abstract][Full Text] [Related]
4. Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
Petersenn S; Unger N; Hu K; Weisshaar B; Zhang Y; Bouillaud E; Reséndiz KH; Wang Y; Mann K
J Clin Pharmacol; 2012 Jul; 52(7):1017-27. PubMed ID: 21673137
[TBL] [Abstract][Full Text] [Related]
5. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
Petersenn S; Bollerslev J; Arafat AM; Schopohl J; Serri O; Katznelson L; Lasher J; Hughes G; Hu K; Shen G; Reséndiz KH; Giannone V; Beckers A
J Clin Pharmacol; 2014 Nov; 54(11):1308-17. PubMed ID: 24800725
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
Chen X; Shen G; Jiang J; Liu H; Hu K; Darstein C; Lasher J; Hu P
Clin Ther; 2014 Aug; 36(8):1196-210. PubMed ID: 25012727
[TBL] [Abstract][Full Text] [Related]
8. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels.
Shenouda M; Maldonado M; Wang Y; Bouillaud E; Hudson M; Nesheiwat D; Hu K
Am J Ther; 2014; 21(3):164-73. PubMed ID: 22713526
[TBL] [Abstract][Full Text] [Related]
9. Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.
Horsmans Y; Hu K; Ruffin M; Wang Y; Song D; Bouillaud E; Wang Y; Mazur D; Botha FP; Heuman DM
J Clin Pharmacol; 2012 Apr; 52(4):552-8. PubMed ID: 22282526
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.
Wolin EM; Hu K; Hughes G; Bouillaud E; Giannone V; Resendiz KH
Cancer Chemother Pharmacol; 2013 Aug; 72(2):387-95. PubMed ID: 23765178
[TBL] [Abstract][Full Text] [Related]
11. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Breitschaft A; Hu K; Hermosillo Reséndiz K; Darstein C; Golor G
Diabetes Res Clin Pract; 2014 Mar; 103(3):458-65. PubMed ID: 24461109
[TBL] [Abstract][Full Text] [Related]
12. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Kvols LK; Oberg KE; O'Dorisio TM; Mohideen P; de Herder WW; Arnold R; Hu K; Zhang Y; Hughes G; Anthony L; Wiedenmann B
Endocr Relat Cancer; 2012 Oct; 19(5):657-66. PubMed ID: 22807497
[TBL] [Abstract][Full Text] [Related]
13. Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.
Ben-Shlomo A; Melmed S
IDrugs; 2007 Dec; 10(12):885-95. PubMed ID: 18041687
[TBL] [Abstract][Full Text] [Related]
14. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.
Henry RR; Ciaraldi TP; Armstrong D; Burke P; Ligueros-Saylan M; Mudaliar S
J Clin Endocrinol Metab; 2013 Aug; 98(8):3446-53. PubMed ID: 23733372
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.
Dietrich H; Hu K; Ruffin M; Song D; Bouillaud E; Wang Y; Hasskarl J
Eur J Endocrinol; 2012 May; 166(5):821-8. PubMed ID: 22383336
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the absorption, metabolism and excretion of [¹⁴C]pasireotide in healthy volunteers using accelerator mass spectrometry.
Lin TH; Hu K; Flarakos J; Sharr-McMahon M; Mangold JB; He H; Wang Y
Cancer Chemother Pharmacol; 2013 Jul; 72(1):181-8. PubMed ID: 23680921
[TBL] [Abstract][Full Text] [Related]
17. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.
Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ
Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624
[TBL] [Abstract][Full Text] [Related]
18. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
Samson SL
Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
[TBL] [Abstract][Full Text] [Related]
19. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.
van der Hoek J; de Herder WW; Feelders RA; van der Lely AJ; Uitterlinden P; Boerlin V; Bruns C; Poon KW; Lewis I; Weckbecker G; Krahnke T; Hofland LJ; Lamberts SW
J Clin Endocrinol Metab; 2004 Feb; 89(2):638-45. PubMed ID: 14764775
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]